Sign In
Buy SYBX
$1.20
+0.0500 (+4.35%)
At Close: Jul 31, 2026
Synlogic Announces Closing of $21.0 Million Underwritten Public Offering
04:15pm, Tuesday, 03'rd Oct 2023
CAMBRIDGE, Mass., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform
Synlogic Announces Pricing of $21.0 Million Underwritten Public Offering
07:00am, Friday, 29'th Sep 2023
CAMBRIDGE, Mass., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform
Synlogic Announces Publication of Synpheny-1 Phase 2 Study of Synthetic Biotic for Phenylketonuria in Nature Metabolism
11:15am, Thursday, 28'th Sep 2023
CAMBRIDGE, Mass., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform
Why Is Synlogic (SYBX) Stock Down 6% Today?
09:13am, Thursday, 28'th Sep 2023
Synlogic (NASDAQ: SYBX ) stock is sliding lower on Thursday after the biopharmaceutical company announced a reverse split for its shares. According to a press release from Synlogic, the company enact
Synlogic Announces Reverse Stock Split
12:30pm, Wednesday, 27'th Sep 2023
CAMBRIDGE, Mass., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform
Synlogic to Participate in Chardan's Genetic Medicines Conference
07:00am, Thursday, 21'st Sep 2023
CAMBRIDGE, Mass., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform
Synlogic Announces CEO Aoife Brennan Named to PharmaVoice 100
11:00am, Tuesday, 19'th Sep 2023
CAMBRIDGE, Mass., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform
Synlogic, Inc. (SYBX) Reports Q2 Loss, Misses Revenue Estimates
10:00am, Thursday, 10'th Aug 2023
Synlogic, Inc. (SYBX) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to loss of $0.22 per share a year ago.
Synlogic to Present at the Jefferies Global Healthcare Conference
06:50am, Tuesday, 23'rd May 2023
CAMBRIDGE, Mass., May 23, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today announced that Aoife Brennan, M.B. Ch.B.,
3 Penny Stocks That Could Turn $1,000 into $10,000 in a Year
12:38pm, Thursday, 11'th May 2023
Turning $1,000 into $10,000 in a year in the stock market is undoubtedly a lofty goal. Make no bones about it, it's not particularly likely to happen.
Synlogic, Inc. (SYBX) Reports Q1 Loss, Lags Revenue Estimates
09:10am, Thursday, 11'th May 2023
Synlogic, Inc. (SYBX) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to loss of $0.22 per share a year ago.
3 Megatrend Stocks to Buy for 10x Potential Returns
05:12pm, Friday, 28'th Apr 2023
Megatrends exist across many thematic areas of the stock market. Identifying these trends usually involves analyzing key factors such as technological breakthroughs, social change, urbanization, clima
Synlogic, Inc. (SYBX) Reports Q4 Loss, Misses Revenue Estimates
09:13am, Wednesday, 29'th Mar 2023
Synlogic, Inc. (SYBX) delivered earnings and revenue surprises of 7.69% and 73.50%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Synlogic, Inc. (SYBX) Upgraded to Buy: Here's Why
01:33pm, Monday, 16'th Jan 2023
Synlogic, Inc. (SYBX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Synlogic, Inc. (SYBX) Reports Q3 Loss, Tops Revenue Estimates
09:47am, Thursday, 10'th Nov 2022
Synlogic, Inc. (SYBX) delivered earnings and revenue surprises of -8.70% and 93.71%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
